INVESTIGATION OF THE EFFICACY AND TOLERABILITY OF DR MICHAELS®
(also branded as ECZITINEX® andITCHINEX ECZITINEX®) TOPICAL PRODUCTS IN
THE TREATMENT OF ATOPIC DERMATITIS IN CHILDREN

K. FRANÇA1,14, J. HERCOGÓVÁ2,3, M. FIORANELLI4, S. GIANFALDONI5,
A.A. CHOKOEVÀ6,7, G. TCHERNEV8, U. WOLLINA9, M. TIRANT10, P. BAYER10,
M. COBURN10, M. SMITH10, B. DONNELLY10, T. KENNEDY10, J. GAIKOR10,
M. ARORA10, L. CLEWS10, F. NOVOTNY11, M.G. ROCCIA12, G.K. MAXIMOVI13
and T. LOTTI15

1Department of Dermatology & Cutaneous Surgery, Department of Psychiatry & Behavioral Sciences, Institute for Bioethics & Health Policy, University of Miami Miller School of Medicine, Miami, FL, USA; 2nd Medical Faculty, Charles University; Bulovka Hospital, 9Institute of Clinical and Experimental Medicine, Prague, Czech Republic; 3Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy; 4Dermatological Department University of Pisa, Pisa, Italy; 5“Onkodermia”-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; 6Department of Dermatology and Venereology, Medical University of Plovdiv, Medical Faculty, Plovdiv, Bulgaria; 7Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria; 8Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany; 9Psoriasis & Skin Clinic, Melbourne, Australia; 10PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic; 11University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India; 12Department of Medicinal Information and Non-interventional Studies, Bulgarian Drug Agency, Sofia, Bulgaria; 13Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi “G. Marconi”, Rome, Italy; 14Chair of Dermatology, University of Rome “G. Marconi” Rome, Italy

Atopic eczema is a chronic relapsing inflammatory skin disorder, characterized clinically by intensely pruritic eczematous skin lesions and a defective epidermal barrier. It affects more than 15% of children and up to 10% of adults, which makes the disease a social health problem still without a challenging treatment. The aim of this study was to evaluate the efficacy and tolerability of Dr Michaels® (Eczitinex®) topical product family in the treatment of atopic dermatitis in children. We studied a group of 30 patients (17 female, 13 male), aged 5 to 13 (mean age: 9), affected by atopic dermatitis since they were newborn. All patients had been unsuccessfully treated with conventional anti-inflammatory therapies and ceased treatment 2 weeks before commencing research. The patients were treated with Dr Michaels® (Eczitinex® and Itchinox®) product family including a moisturising bar, topical ointment and PSC 900 oral herbal formulation. The treatment was evaluated clinically and photographically at 0, 1, 2, 4, 6, 8, 10, 12, and 14 weeks. Twenty-eight patients showed a significant improvement of cutaneous rashes and pruritus on the first week of treatment, with a complete remission at 10-12 weeks. Only two patients, brother and sister respectively, showed a slow response to treatment and reported an increasing itching. Following 14 weeks of treatment with the Dr Michaels® (Eczitinex® and Itchinox®) product family, patients demonstrated complete resolution of their AD. All patients showed a marked improvement in their condition within 3 days of treatment with most of the lesions and symptoms totally resolved within 10 to 12 weeks of treatment with Dr Michaels® (Eczitinex® and Itchinox®) family of products. This clinical report highlights that the Dr Michaels® (Eczitinex® and Itchinox®) product family is a safe and effective treatment option for AD.